Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight Rating

Benzinga Newsdesk www.benzinga.com Neutral 71.4%

Neg 0% Neu 71.4% Pos 0%

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating.